CRDF
Cardiff Oncology, Inc.
There isn't enough reported data to score CRDF yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CRDF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CRDF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRDF PE Valuation
CRDF has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CRDF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CRDF's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CRDF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.55 | +$0.25 |
| Q2 2026 | -$0.60 | +$0.28 |
| Q1 2026 | -$0.67 | +$0.26 |
| Q4 2025 | -$0.69 | +$0.26 |
| Q3 2025 | -$0.80 | +$0.14 |
| Q2 2025 | -$0.88 | +$0.03 |
| Q1 2025 | -$0.93 | -$0.03 |
| Q4 2024 | -$0.95 | -$0.02 |
CRDF is still losing money, but far less than before: $0.55 per share over the past year, against $2.80 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CRDF on earnings quality, reporting a profit while its opponent remains loss making.
CRDF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $171K | +43% |
| Q2 2026 | $104K | -14% |
| Q1 2026 | $41K | -62% |
| Q4 2025 | $243K | +61% |
| Q3 2025 | $120K | -27% |
| Q2 2025 | $121K | -26% |
| Q1 2025 | $109K | -47% |
| Q4 2024 | $151K | -3.2% |
CRDF's revenue is growing: $171,000 last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5391% | +4587 points |
| Q2 2026 | -9245% | +2967 points |
| Q1 2026 | -31341% | -18147 points |
| Q4 2025 | -3221% | +5105 points |
| Q3 2025 | -9978% | -2341 points |
| Q2 2025 | -12212% | -4516 points |
| Q1 2025 | -13195% | -7861 points |
| Q4 2024 | -8326% | -1703 points |
CRDF's operating margin was −5391% last quarter, up 4587 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CRDF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CRDF on profitability, with a higher operating margin.
CRDF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.9M | +$974K |
| Q4 2025 | -$6M | +$4.3M |
| Q3 2025 | -$10.9M | -$396K |
| Q4 2024 | -$10.3M | -$3.1M |
| Q3 2024 | -$10.5M | -$2.2M |
| Q2 2024 | -$9.2M | -$1.8M |
| Q1 2024 | -$7.8M | +$847K |
| Q4 2023 | -$7.1M | +$2.3M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with CRDF at down 29%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CRDF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +7.8M shares |
| 1 year | +14% | +9.3M shares |
| 3 years | +71% | +31.5M shares |
| 5 years | +97% | +37.4M shares |
| Available history | +669% | +66.3M shares |
CRDF has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRDF Net Leverage
CRDF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CRDF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CRDF's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRDF PE vs Healthcare Sector
CRDF has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRDF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.96 | 24% below |
| 20 week MA | $1.01 | 28% below |
| 50 week MA | $1.57 | 54% below |
| 100 week MA | $2.35 | 69% below |
| 200 week MA | $2.29 | 68% below |
CRDF is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CRDF on trend strength, trading above more of its moving averages.
CRDF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $18.9 | +1377% |
| 2021 | $18.9 | $6.45 | -66% |
| 2022 | $6.45 | $1.26 | -80% |
| 2023 | $1.26 | $1.48 | +17% |
| 2024 | $1.48 | $4.32 | +192% |
| 2025 | $4.32 | $3.17 | -27% |
| 2026 YTD | $3.17 | $0.73 | -77% |
CRDF's yearly returns have swung widely, from +1377% in 2020 to −80% in 2022. It's down 77% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRDF on returns for 2026, with the stronger performance.